Bicuspid Aortic Valve: Identifying Knowledge Gaps and Rising to the Challenge From the International Bicuspid Aortic Valve Consortium (BAVCon)
on behalf of the BAVCon Investigators*

Circulation. 2014;129:2691-2704
doi: 10.1161/CIRCULATIONAHA.113.007851

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/129/25/2691

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
Bicuspid Aortic Valve
Identifying Knowledge Gaps and Rising to the Challenge
From the International Bicuspid Aortic Valve Consortium (BAVCon)

Hector I. Michelena, MD; Siddharth K. Prakash, MD, PhD; Alessandro Della Corte, MD, PhD; Malenka M. Bissell, MD, BM, MRCPCH; Nandan Anavekar, MB, BCH; Patrick Mathieu, MD; Yohan Bossé, PhD; Giuseppe Limongelli, MD; Eduardo Bossone, MD; D. Woodrow Benson, MD, PhD; Patrizio Lancellotti, MD, PhD; Eric M. Isselbacher, MD; Maurice Enriquez-Sarano, MD; Thoralf M. Sundt III, MD; Philippe Pibarot, DVM, PhD; Artur Evangelista, MD, PhD; Dianna M. Milewicz, MD, PhD; Simon C. Body, MBChB, MPH; on behalf of the BAVCon Investigators*

Everything should be kept as simple as possible, but no simpler.

—Albert Einstein

Since its estimated first description >500 years ago by Leonardo da Vinci,2 the bicuspid aortic valve (BAV) has progressively built a reputation; initially, as a curious valvular phenotype with a tendency to develop obstruction and insufficiency. In more contemporary times, however, the BAV is recognized as underlying almost 50% of isolated severe aortic stenosis cases requiring surgery,3 and has been extensively associated with ominous outcomes such as bacterial endocarditis and aortic dissection.4 These associations, coupled with the high prevalence of BAV in humans,5 have prompted investigative efforts into the condition, which although insightful, have generated more questions than answers. This review describes our current knowledge of BAV, but, more importantly, it highlights knowledge gaps and areas where basic and clinical research is warranted. Our review has 2 sections. The first section outlines the multifaceted challenge of BAV, our current understanding of the condition, and barriers that may hamper the advancement of the science. The second section proposes a roadmap to discovery based on current imaging, molecular biology, and genetic tools, recognizing their advantages and limitations.

DOI: 10.1161/CIRCULATIONAHA.113.007851
significance of aortic valve and aorta disease in the family history, may hinder the prompt diagnosis of BAV.

A Valvuloaortopathy With Varied Phenotypes and Unpredictable Outcomes

Given the high incidence of BAV dysfunction requiring surgical intervention and the high incidence of associated TAA formation8–10,14–18 (Table), the BAV condition should be viewed as a valvuloaortopathy, at least from the nosological perspective. Phenotypically, all possible combinations and degrees of cusp fusion (with or without the presence of a fibrous ridge [raphe] between the conjoined cusp) can be observed by echocardiography (Figures 1 and 2). The resulting 2 aortic cusps are usually asymmetrical with 3 identifiable sinuses of Valsalva, and only 5% are estimated to be symmetrical,19 each cusp occupying 180 degrees of the annular circumference. A symmetrical BAV without raphe is often referred to as a true BAV and has only 2 identifiable sinuses of Valsalva (Figure I in the online-only Data Supplement).

Even if normally functioning or minimally dysfunctional (as determined by echocardiography), the 2 cusps of most BAVs exhibit asymmetrical systolic excursion with marked bending strain in systole,20 high stress in the raphal area of the conjoined cusp,21 uneven systolic flow patterns, and intrinsic morphological stenosis.22 The ascending aorta (including the root [sinuses of Valsalva] and the tubular-ascending portion) also displays a spectrum of aneurysmal phenotypes (Figure 3),23–25 tubular-ascending aorta dilatation being the most common phenotype (60%–70% of dilated aortas) with the fastest growing rate in adults (≈0.4–0.6 mm/y),25,26 irrespective of BAV morphology and function.23 However, there is also a predominant sinus of Valsalva dilatation phenotype that is less common (≈25% of dilated aortas) and associated with type 1 (right-left cusp fusion) BAV morphology25 and male sex.25 This root phenotype has been associated with faster

Table. Contemporary Clinical Outcomes in BAV

<table>
<thead>
<tr>
<th>Study Features, Clinical Outcomes</th>
<th>Contemporary Clinical Outcomes BAV Studies*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication year</td>
<td>Michela et al8</td>
</tr>
<tr>
<td>Clinical setting</td>
<td>Tzemos et al9</td>
</tr>
<tr>
<td>Inclusion characteristics</td>
<td>Davies et al10</td>
</tr>
<tr>
<td></td>
<td>Russo et al15</td>
</tr>
<tr>
<td></td>
<td>Borger et al14‡</td>
</tr>
<tr>
<td></td>
<td>McKellar et al17</td>
</tr>
<tr>
<td></td>
<td>Girdauskas et al18§</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>212</td>
</tr>
<tr>
<td>Baseline age, y, mean±SD</td>
<td>32±20</td>
</tr>
<tr>
<td>Follow-up years, mean±SD</td>
<td>15±6</td>
</tr>
<tr>
<td>Survival</td>
<td>90% at 20 y</td>
</tr>
<tr>
<td>Heart failure</td>
<td>7% at 20 y</td>
</tr>
<tr>
<td>Aortic valve surgery</td>
<td>24% at 20 y</td>
</tr>
<tr>
<td>Reason for aortic valve surgery</td>
<td>AS 67%</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>2%</td>
</tr>
<tr>
<td>Aneurysm formation (definition, mm)</td>
<td>39% (&gt;40 mm)</td>
</tr>
<tr>
<td>Aortic surgery (for aneurysm)</td>
<td>5% at 20 y</td>
</tr>
<tr>
<td>Aortic dissection</td>
<td>0% at 20 y</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| AR indicates aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; BAV, bicuspid aortic valve; and SD, standard deviation.
*Outcomes reported as percentage only were not reported within Kaplan-Meier survival analyses. Survival in the first 3 studies (Michela,8 Tzemos,9 and Michela10) was not different than that of the general population. Survival in the McKellar17 study was inferior to that of the general population, and the rest of the studies were not compared with the general population.
†This study compared BAV patients with aneurysms vs tricuspid aortic valve patients with aneurysms. The incidence of aortic dissection was the same for both groups with superior survival in BAV patients and both groups dissecting at similar aortic diameters.
‡This study suggested that patients with aortic dimension ≥45 mm at the time of AVR should have the aorta concomitantly repaired; the basis of the current recommendations.
§This study included consecutive patients with isolated AVR performed for aortic stenosis only. However, 21 patients with predominant dilatation of the root (mean diameter, 44 mm) and severe aortic regurgitation who underwent AVR were followed in parallel for a mean of 10 years and 2 acute dissections occurred.
tubular-ascending aorta dilatation,\textsuperscript{26} and aortic regurgitation is, in turn, related to faster root dilatation.\textsuperscript{25} In addition, half of BAV patients with severe aortic regurgitation exhibit a significant loss of medial elastic aortic fibers,\textsuperscript{27} and a root phenotype with aortic regurgitation has recently been associated with a higher risk of aortic dissection in a limited BAV subgroup.\textsuperscript{18} Thus, we hypothesize that a root phenotype and aortic regurgitation could represent higher TAA-risk BAV subsets. Importantly, the dilatation rates are variable, independent of the BAV phenotype, and, for the most part, unpredictable in BAV patients.\textsuperscript{25} The underlying mechanisms responsible for such varied BAV-associated valvular aortic phenotypes remain unknown, and, despite the aforementioned valvular pathophysiologic insights, why a BAV becomes stenotic, another regurgitant, another is associated with aortic dissection, and yet another remains functional throughout a lifetime, remains fundamentally unknown and unpredictable, a critical knowledge gap that remains unresolved since its first description by Roberts >40 years ago.\textsuperscript{19} More concerning is the fact that there is only scarce insight as to why a few unfortunate BAV patients will incur aortic dissection in their lifetime but many will not.\textsuperscript{10} Indeed, available clinical tools attempting to risk stratify BAV patients for aortic catastrophes (ie, aortic size) are only modestly useful because catastrophic aortic events may occur in patients with less-than-severe enlargement, below danger-zone cutoffs,\textsuperscript{29} whereas patients with aortic diameters well above these cutoffs may never dissect or dissect late.\textsuperscript{10,30}

\textbf{Innocent Bystander or Primary Disease?}

Although the BAV phenotype presents most commonly in isolation in adults (only 15\% associated congenital heart abnormalities versus 50\% in young children),\textsuperscript{7,10} BAV relates to several congenital and genetic disorders with cardiovascular manifestations, often associated with congenital left-sided obstructive lesions (ie, coarctation of the aorta, Shone complex),\textsuperscript{7} ventricular septal defect,\textsuperscript{31} and syndromic conditions (ie, Turner, Loeys-Dietz), and familial TAA and dissection disease due to smooth muscle \(\alpha\)-actin (\textit{ACTA2}) gene mutations, as well.\textsuperscript{3,32,33} Despite the evidence of an autosomal dominant pattern of BAV inheritance with variable expression and incomplete penetrance in families,\textsuperscript{34,35} and the identification of mutations in \textit{NOTCH1} (associated with BAV and valvular calcium-deposition derepression), as well,\textsuperscript{36} and \textit{GATA5} (associated with BAV and aortopathy) in rare families with BAVs,\textsuperscript{37} the genetic causes and their potential clinical implications for the majority of BAV patients remain largely unknown. In light of this genetic and developmental conundrum, is it possible that the BAV may be a by-product of a more widespread genetic alteration involving the aorta and other structures of the developing heart such that the BAV is sometimes merely an innocent bystander? Or are there more restricted alterations limited to the aortic valve, with distinct types of primary BAV disease: a primary valvular type wherein a BAV is the main feature, and, thus, the most probable complication is the need for aortic valve replacement (AVR), and another primary type wherein a valvulooaortopathy predominates with potential aortic valve dysfunction and TAA formation with augmented aortic dissection risk? Or is there a complex form of BAV disease more often uncovered in childhood because of its symptomatic presentation and another simple form more often uncovered in adults because of its paucity of symptoms? Indeed, BAV is frequently associated with complex conditions leading to diagnosis in childhood (ie, Shone complex),\textsuperscript{38} whereas it is found mostly in isolation (with or without TAA).
when diagnosed in adults, although some complex features such as aortic coarctation may be carried into adulthood. Patterns and rates of aortic dilatation may also differ between pediatric and adult populations, and aortic dissection is extremely rare in young BAV children. Answers to these questions are far from being a mere academic curiosity, given the direct patient care impact on risk stratification that their elucidation would provide.
Natural History of BAV: What Do We Know?

Prospective, long-term clinical follow-up of individuals with BAV diagnosed at birth by routine screening would be ideal in decoding the natural history of BAV and its complications. However, massive echocardiographic screening of entire populations at birth and subsequent very long-term (ie, lifelong) follow-up are not feasible from resource and time perspectives. Retrospective identification and phenotyping of BAV patients with prospective follow-up is thus an important clinical research strategy.

Our knowledge of the contemporary BAV natural history stems from population-based and tertiary-referral–based retrospective studies (Table) where the BAV condition began at echocardiographic diagnosis,8–10 with the inevitable exclusion of BAV patients who never came to medical attention (remaining undiagnosed) and the rejection of uncertain BAV diagnoses.10 The notion of natural history is also tainted by pharmacological interventions and guideline-driven surgeries for life-threatening events or their prevention, best illustrated by prophylactic aorta surgical repair recommended by guidelines when the ascending aortic diameter is ≥50 mm (recently changed to >55 mm by new, 2014 AHA/ACC guidelines49), or ≥45 mm if concomitant AVR is being performed,31 where the former represents a non–evidence-based extrapolation of Marfan syndrome guidelines and the latter is supported by 2 observational studies6,30 (importantly, there are no randomized trials to inform the timing of prophylactic surgery for any thoracic aneurysmal disease). Therefore, the information gathered by clinical research is the clinical history of BAV instead of natural history. Nonetheless, mean follow-up times up to 16 years and a maximum of 25 to 30 years have been attained,10 and important clinical history observations have emerged from contemporary studies (Table). After mean follow-ups ranging from 9 to 16 years, it is apparent that, despite increased risks of early aortic valve dysfunction, premature congestive heart failure, AVR, endocarditis, TAA formation, aortic dissection (Table), and complications related to accompanying ailments (ie, aortic coarctation), the 25-year survival of BAV patients after echocardiographic diagnosis is not different from that of the general population. This is explained in part by the young age at BAV diagnosis (mean, 32–35 years) and the low risk associated with contemporary AVR, and also by the fact that the incidence of life-threatening complications is low.10 Indeed, the incidence of aortic dissection in all BAV patients across 3 decades (1980–2010) has been estimated to be 8 times higher than in the general population, but still remains exceedingly low at 0.03% per year. This exercise is usually exhausted before considering the result of BA V patients with endocarditis being younger and having fewer comorbidities than tricuspid valve patients despite exhibiting higher endocarditis-related complications. Thus, endocarditis in age-matched BAV patients could indeed carry a higher mortality, a hypothesis that requires further investigation.

BAV: Victim of Parsimony?

In medicine, diagnostic parsimony advocates that the source of multiple symptoms should be adjudicated to only 1 disorder: “among competing hypothesis, favor the simplest one.”47 This exercise is usually exhausted before considering the prospect of multiple pathophysiologic mechanisms occurring in the same patient. Clinical parsimony in BAV is best exemplified by the assumption that BAV-related aortopathy is clinically equivalent to the aortopathy of Marfan syndrome, which has led to the extrapolation of elective surgery aortic diameter cutoffs from Marfan guidelines to BAV guidelines.41 There are pathological similarities between BAV aortas and the aortas of patients with Marfan syndrome, a condition whose genetic basis48 and natural history49 have been definitively elucidated. These similarities include the fragmentation loss of elastic fibers, decreased numbers of smooth muscle cells, and increased deposition of proteoglycans in the medial layer of the aorta, termed medial degeneration.50,51 Interestingly, however, 100% of Marfan patients with severe aortic regurgitation and TAA exhibit a severe loss of medial elastic fibers in comparison with 47% of similar BAV patients.32 Other similarities include an imbalance of extracellular matrix–degrading enzymes (metalloproteinases) and their inhibitors that has been described for both entities.50–52 These biological similarities do not have clinically equivalent implications, however, as evidenced by significantly decreased life expectancy due to aortic dissection30 in patients with Marfan syndrome who do not undergo prophylactic aortic surgery. The average age of death in these patients is only 32 years, and acute aortic dissection and its complications account for 80% of these deaths.49 In contrast, the mean age of BAV patients at entry into the first contemporary BAV clinical history study was also 32 years of age,8 with a subsequent 20-year risk of elective aneurysm surgery of only 5% and aortic dissection identical to that of the general population, and no documented aortic dissections (Table). In addition, despite BAV being >100 times more common than Marfan,33 the International Registry of Aortic Dissection has shown that the Marfan syndrome still accounts for 50% of aortic dissections in patients <40 years of age (versus 9% for BAV).54 Moreover, the risk of aortic dissection during pregnancy is significantly higher with Marfan syndrome55 than with BAV.56 Nonetheless, aortic dilatation (>40 mm) was present in <10% of pregnant BAV women in the study by McKellar et al56 on BAV and pregnancy. Thus,
the risk of dissection in pregnant BAV patients with dilated aortas remains unknown. A large BAV registry may offer sufficient aortic diameter variability to study this population. Finally, despite faster progression of aortic dilatation in BAV patients with aneurysms in comparison with tricuspid aortic valve patients with aneurysms, the incidence of aortic catastrophes was reported as equal to that of aortic dissection in BA patients with similar aortic diameters, although more BAV patients underwent elective aorta repair. These data suggest that the clinical outcome of the BAV-aortopathy may resemble more that of the general population with aneurysms than that of aortopathy of Marfan syndrome, a notion that has been recognized in the new ACC/AHA valvular heart disease management guidelines by increasing the elective aorta repair cut-off to 55 mm.

The notion of a common pathogenic pathway leading to BAV and its complications is also challenged by clinical observations. It is fundamentally unknown why a child develops severe BAV dysfunction, and an adult with moderate BAV dysfunction develops aortic dissection, and a healthy 89-year-old individual is incidentally found to have a minimally dysfunctional BAV. It is thus apparent that undiscovered, complex genetic and environmental pathogenic factors are at play, and that pathogenic parsimony is not the answer. This concept will be critical when deciphering the underpinnings of BAV stenosis. Recent evidence suggests an active inflammatory process with angiogenesis, fibrosis, and calcification resembling bone formation involved in the pathogenesis of tricuspid aortic valve stenosis. Are these the same molecular pathways involved in BAV stenosis? Why does BAV stenosis occur decades earlier than tricuspid aortic valve stenosis? Is mechanical stress more important in the pathogenesis of BAV stenosis? What role does genetic predisposition to calcification play in BAV stenosis?

BAV: Victim of Compartmentalization?

Failure to recognize its heterogeneity has made BAV a casualty of the efforts to explain its complications from oversimplified and rigid viewpoints. For example, there is considerable debate as to whether hemodynamic alterations related to BAV or a genetic defect leading to aortic disease is the cause of TAA in BAV patients. Data are available to support both etiologies. A genetic defect driving the BAV-associated aortopathy is supported by the fact that unaffected first-degree relatives of BAV patients may exhibit aneurysmal aortic disease. Additionally, tricuspid aortic valve patients with the same degree of aortic stenosis have a lower incidence of TAA than BAV patients. Similarly, although the aortic dilatation rate may decrease after AVR, AVR does not halt aortic dilatation progression in BAV, and late post- AVR aortic dissections do occur (Table). It is nevertheless evident that an association between overt BAV dysfunction and TAA formation exists, but is it causal? Recent studies also suggest that fluid hemodynamics and aortic wall stress in the BAV aorta are abnormal even in the absence of echocardiographically defined overt valvular dysfunction, which not only represents proof of concept that a normally functioning BAV is intrinsically dysfunctional, but also suggests that hemodynamic-induced stress likely contributes to aortic dilatation. Although transcriptional, protein, and histopathologic alterations have been characterized in aortas of BAV patients, it remains to be elucidated whether these biochemical imbalances occur spontaneously or result from altered cellular mechanics and gene expression in response to strain and shear stress in the BAV aorta, or both.

The BAV has also been compartmentalized from the clinical outcomes perspective, particularly when studied in pediatric versus adult populations. The controversy surrounding the clinical significance of specific BAV phenotypes exemplifies this issue. Although some cross-sectional studies in adults suggest associations between type 2 BAV and valvular stenosis, and between type 1 BAV and regurgitation, adult cohort populations show no evidence of associations between BAV phenotypes and clinical outcomes (ie, AVR). Conversely, pediatric populations exhibit an association between type 2 BAV (right-noncoronary fusion) and accelerated valve dysfunction (both stenosis and regurgitation) leading to valve intervention. Thus, the clinical significance of BAV phenotypes may differ between adults and children, which may explain why the prevalence of the right-noncoronary phenotype is higher in children (30%–40%) than in adults (20%), probably reflecting a natural selection process whereby phenotypes less prone to dysfunction persist into adulthood. At the same time, many patients with type 2 BAV will not develop significant valvular dysfunction, suggesting that factors other than just phenotype dictate the degree of valvular dysfunction. Identifying these factors would be the first step toward determining who with BAV is at risk for valvular complications, and may begin to shed light on the molecular mechanisms responsible for valvular dysfunction, a critical initial step for targeted therapies.

Current Clinical Approach to Adult BAV Patients

Although derived mostly from consensus, after a diagnosis of BAV is made, the following management principles should be observed: (1) Echocardiographic screening of first-degree family members is recommended to rule out BAV and aortopathy. (2) Aortic coarctation must be ruled out by echocardiography or computed tomography/magnetic resonance. (3) The echocardiographic monitoring interval of BAV function should follow current valvular and echocardiography appropriateness guidelines. (4) Appropriate dental hygiene must be recommended for endocarditis prevention. (5) Surgical intervention timing for BAV dysfunction should follow current valvular guidelines. (6) If root or ascending aorta dilatation is detected by echocardiography (ie, ≥40 mm), confirmation of size by computed tomography/magnetic resonance is recommended. If no significant measurement disparities are found between techniques, a repeat echocardiography at 6 months is recommended; and, if aortic size remains stable, without a family history of aortic dissection, annual aortic imaging is then recommended. (7) Aggressive treatment of hypertension and tobacco cessation must be pursued in BAV patients with aortopathy. (8) Elective intervention for ascending aeurysms is indicated when the aorta measures ≥55 mm (if no family history of aortic dissection exists), when it measures ≥45 mm and concomitant AVR is being performed, or when dilatation rate is ≥0.5 cm/year. (9) In selected patients with aortic dilatation
and family history of thoracic aortic disease, genetic consultation and testing may be useful in determining timing of elective aortic intervention. (10) BAV without aortopathy and no valve dysfunction should be screened every 3 to 5 years with echocardiography to rule out the development of aortopathy/valvulopathy, and patients who have undergone isolated AVR must continue yearly root and ascending aorta imaging to rule out the development or worsening of dilatation. (11) After surgical replacement of the ascending aorta, the arch and descending thoracic aorta should be monitored every 3 to 5 years with computed tomography/magnetic resonance.

**Rising to the Challenge: A Road Map to Discovery**

**Advancing the Science**

To advance the science, it is essential to identify clinical targets. Although life-threatening aortic complications are the most feared, the largest population-based outcomes study with the longest follow-up showed that severe BAV dysfunction driven by valvular stenosis and requiring AVR is, by far, the most common morbidity of BAV patients, with >50% of patients requiring AVR within 25 years of their initial diagnosis (Figure 4, Table). Furthermore, AVR occurs a mean of 18 years earlier in BAV patients than in those with a tricuspid valve, usually within the productive years of life. The second most common morbidity is the development of significant aorta dilatation (≥45 mm), which occurs in >25% of BAV patients 25 years after BAV diagnosis (age at BAV diagnosis and aneurysm diagnosis, 35±21 years and 50±17 years, respectively). These observations should focus efforts of basic science on the genetic and pathological mechanisms of BAV stenosis and TAA formation. Accurate classification of BAV phenotypes, coupled with functional aortic flow imaging and the identification of genetic risk variants and circulating biomarkers, could identify patients at high risk for accelerated valvular calcification and TAA formation, as well.

Regarding currently available therapies for BAV, contemporary observations also mandate clinical research to improve surgical repair of the noncalcified purely regurgitant BAV. Despite the prolapse of the conjoined cusp being considered the premier pathomechanism involved in BAV regurgitation, it is now recognized that the prolapse of the nonfused cusp is also prevalent. In addition, the spatial orientation of the true commissures and the size of the aortoventricular junction, as well, are predictors of repair durability. The development of selection criteria and safe platforms for transcatheter aortic valve replacement is critical, because BAV is present in >20% of octogenarians with severe aortic valve stenosis, and BAV patients may also carry a high open AVR risk. Despite the theoretical concern of elliptic deployment of the transcatheter valve in BAV annuli (instead of the ideal circular deployment), and the concern of valve underdeployment, transcatheter delivery and the deployment of Edwards-SAPIEN valves and Core valves in patients with BAV has been proven feasible, but needs further study in large patient cohorts to define the ideal candidates for available platforms and to design new BAV-tailored ones.

 Parsimony and compartmentalization, but, more importantly, a mere lack of data, are responsible for the current controversy surrounding the indication and timing of elective surgical intervention for the aorta in BAV patients. For example, conflicting observational studies prompt entirely different positions on the issue of prophylactic aorta repair during AVR (Table), some suggesting radical replacement of all ascending aortas during AVR and others a more conservative approach based on aortic size and direct inspection of the aorta during AVR. It is obvious that aortic size is (the main tool to stratify the risk of aortic dissection in BAV patients) and evidence of medial degeneration (if it could be determined before catastrophic events) are limited risk stratification tools. Traditionally, we have interpreted aortic dissection to be the result of simple mechanical failure, directly related to the excess aortic wall tension that severe dilatation imposes. However, aortic dissection is likely the final product of a silent...
gathering storm whereby mechanical, biological, and genetic influences act in unison. This is the only plausible explanation as to why aortic size alone is limited as a risk predictor.

Several barriers exist to advancing the science of predicting aortic catastrophes in BAV: (1) Aortic dissection is an uncommon event in BAV, but the reproducibility by modalities is controversial. Some authors report an excellent correlation between aortic measurements by transthoracic echocardiography and computed tomography, whereas others report decreased sensitivity for dilatation detection by echocardiography, and others show systematic underestimation of diameters by echocardiography in comparison with computed tomography.

(2) Functional imaging of the aorta is in its infancy, and molecular imaging of the aorta that reflects underlying pathology is not available. (3) Potential areas such as genetic-based and biomarker-based risk stratification, both of which require very large patient numbers, remain unexplored, in part, because of a relative paucity of genetic and other biomarker candidates for BAV complications.

Rising to the aforementioned challenges calls for several general steps. The first step is to recognize that association does not imply causality, but clever interpretation of associations may steer the design of research to elucidate causality and evaluate prophylactic and secondary treatment strategies. The second step is to develop a collaborative multicenter retrospective and prospective BAV patient registry with homogeneous and rigorous entry criteria (ie, accurate BAV diagnosis and phenotyping with exclusion of unclear cases), where state-of-the-art multimodality imaging, pathology, and genotyping tools are used (Figure 5). The third step is to assemble a panel of experts from different specialties to nonparsimoniously reconcile the clinical, imaging (phenotypic and functional), pathobiology, genetic, and management pieces of the puzzle.

Figure 5. Roadmap for advancing the science. After identifying basic and advanced clinical targets, the critical next steps are precise BAV diagnosis and phenotyping, and accurate aortic size multi-imaging measurement, as well. Advanced imaging allows for additional CT and CMR innovative evaluations. The bidirectional feedback between clinical imaging and pathobiology-genetics (double-headed arrows) leads to biomarker discovery, sophisticated risk stratification, and the development of specific therapies for basic and advanced clinical targets. BAV indicates bicuspid aortic valve; CMR, cardiac magnetic resonance imaging; CT, computed tomography; ECM, extracellular matrix; and TAA, thoracic aortic aneurysm.

**State-of-the-Art Imaging of the BAV and Aorta: An Essential Requirement**

**Echocardiography**

Despite well-recognized transthoracic echocardiographic BAV diagnostic features (Figure II in the online-only Data Supplement) and reasonable phenotyping capability, diagnostic uncertainty may remain in 10% to 15% of patients after echocardiogram. This limitation not only affects patient care (ie, unclear bicuspid status), but also hampers phenotypic-genetic association research efforts. In patients with good-quality transthoracic images who do not have dense BAV calcification, diagnostic sensitivity and specificity are >70% and >90%, respectively. Diagnostic and phenotyping accuracy can be significantly improved with the use of higher-resolution imaging techniques (ie, magnetic resonance, computed tomography, and transesophageal echocardiography), particularly in patients with advanced calcific disease in whom diagnostic accuracy may improve from ≈70% with echocardiography to >90% for magnetic resonance. When ascertaining aortic dimensions, echocardiography may potentially measure obliquely and not perpendicular to the long axis of the aortic flow, rendering inaccurate measurements. In addition, different measurement protocols (ie, inner-edge to inner-edge versus leading-edge to leading-edge and end-diastolic versus end-systolic) result in systematic measurement variation within echocardiography. Furthermore, transthoracic echocardiography measurements of the aortic root are systematically lower than those measured by ECG-gated computed...
tomography angiography. This has important implications with regard to surveillance imaging, because computed tomography angiography should be considered state-of-the-art owing to its higher resolution, but clinical cutoffs for intervention have largely been derived from echocardiography. Another potential risk stratifier that deserves further study in BAV patients is the value of aortic cross-sectional area indexed by height or other anthropometric parameters. Nonetheless, echocardiography remains a validated, state-of-the-art imaging modality for the diagnosis, phenotyping, and hemodynamic assessment of aortic valve dysfunction and the initial assessment of the thoracic aorta.

Magnetic Resonance Imaging
Cardiac MRI (CMR) has gained importance in clarifying questionable BAV diagnoses and imaging the ascending aorta perpendicular to the aortic lumen. More importantly, new CMR techniques have brought us closer to understanding the hemodynamic forces within the ascending aorta in the presence of BAV. Blood flow imaging with 3-dimensional time-resolved, phase-contrast CMR (4-dimensional flow) allows descriptive flow characterization and quantification of aortic wall shear stress, as well (Figure 6). Eccentric systolic jets resulting in abnormal right-handed helical ascending aorta flow have been identified in BAV patients, even in normally functioning BAVs with normal aortic diameters. Furthermore, an increased flow angle (jet eccentricity) was associated with greater aortic growth in BAV patients in a small retrospective cohort, suggesting that the quantification of the hemodynamic contribution in BAV aortopathy could become a novel imaging biomarker for risk stratification. Flow abnormalities appear to depend on BAV phenotype, but the clinical implication of this observation is unknown. CMR may also shed light on the functional aortopathy by quantifying aortic function with aortic strain, distensibility, and pulse wave velocity, but current results are inconclusive; 1 study showed changes in ascending aortic distensibility in young patients with BAV, whereas a larger study including a wide age range of patients could not replicate those findings. CMR offers the unique opportunity to transition from anatomic to dynamic imaging of the ascending aorta, assessing its functional properties and blood flow patterns, as well.

Computed Tomography
Akin to CMR, computed tomography (CT) provides a measurement that is perpendicular to the longitudinal or flow axis of the aorta to correct for the variable geometry of the aorta as it courses through the chest (double-oblique measurement technique, Figure 7). A major advantage of CT is its superior

Figure 6. CMR ascending aortic flow patterns in BAV. A, Normal ascending aortic flow pattern in a healthy volunteer. B, Typical ascending aortic flow pattern in a patient with bicuspid aortic valve; helical flow is seen in the ascending aorta, a forward-moving rotational movement of the aortic blood flow. BAV indicates bicuspid aortic valve; and CMR, cardiac magnetic resonance imaging.

Figure 7. Double-oblique CTA ascending aorta measurement. Figure demonstrates a coronal multiplanar reformation. An imaging plane longitudinal to the aorta (A) results in a subsequent image depicted in B, through which another plane is aligned longitudinal to the aorta (green) and a plane orthogonal to the latter (red) is also prescribed. The resulting image (C) is a plane that is axial to the ascending aorta at the level of the pulmonary arterial bifurcation. CTA indicates computed tomography angiography.
spatial resolution in comparison with both echocardiography and CMR. With faster image acquisition, dynamic imaging of the aortic valve is also feasible with temporal resolutions <100 ms, which may provide information on BAV function. The aortic valve can be planimetered for area, interrogated for morphology, and the presence and patterns of calcification ascertained. BAV patients tend to have large annuli (ie, >23 mm), which may generate discordant less-than-severe aortic stenosis echocardiographic grading with mean gradients of >40 mm Hg and valve areas of >1 cm². A severity-grading tool such as CT-derived aortic valve calcium load may offer an independent platform to reconcile these discrepancies, but it has not been studied in BAV patients.

If headway is to be made in the study of BAV, several imaging research goals must be pursued: (1) CT or MR should be used to diagnose and determine specific BAV phenotypes in patients with unclear echocardiographic evaluation; (2) CT or MR should be pursued for measurement of the entire thoracic aorta when it appears dilated by echocardiography (ie, measures >40 mm) or when echocardiographic mid-distal ascending aorta visualization is limited; (3) determination of the best aorta measurement protocols that reconcile differences between echocardiography, CT, and MR, with standardization of these measurement methods for each technique, with the premise that the gold standard should be CT or MR (higher resolution and optimal cross-sectional acquisition), and the caveat that current clinical cutoffs were mostly derived from echocardiography; (4) long-term imaging and clinical follow-up of a BAV cohort in which the aforementioned imaging was performed, along with baseline MRI–4-dimensional aortic flow data, should be pursued, and DNA and surgical valve/aorta specimens banked for molecular and genetic studies; and (5) quantification and characterization of calcification patterns of BAVs by CT according to BAV phenotype.

Pathobiology and Genetics: Pathways Toward Individualized Risk Stratification and Care of the BAV Patient

Pathobiology

Previous studies have identified molecular signaling pathways responsible for aortic valve embryological development. The Notch signaling pathway is involved in the formation of the outflow tract and the endocardial-mesenchymal transition, an important process involved in valvulogenesis. The development of the semilunar valves is intimately linked to outflow tract septation and aorta/aortic arch remodeling. Neural crest cells participate in the formation of the vascular smooth cells of the ascending aorta, present in the late phase of semilunar valve development. The disruption of Notch signaling in mice is associated with defective neural crest cells patterning, unequal aortic valve leaflets with a bicuspid-like morphology and disorganized aortic wall histology. These observations suggest a potential signaling pathway abnormality linked to both aortic valve and aorta embryology.

Decreased endothelial nitric oxide synthase expression may be related to BAV formation in mice and could modulate valvular mineralization. Also, dysregulation of the transforming growth factor-β pathway in BAV aortas in comparison with tricuspid aortic valve aortas has been suggested. In addition to and consistent with the flow abnormalities described by CMR, an asymmetrical pattern of histological abnormalities and nonhomogeneous distribution of biomolecular changes is observed in the ascending aortas of BAV patients.

Figure 8. The roadmap to translate genetic discoveries into clinical applications. A key priority is to identify candidate genes for BAV-associated phenotypes, a critical step in the development of translational therapies. First, suggestive findings from family-based or case-control studies must be independently validated in separate groups of BAV cases. The roles of candidate genes in valve development or disease can then be assessed by using in vitro or animal models, which may facilitate the development of interventions that target these genes and biological pathways. Finally, genetic tests or therapies need to be tested in randomized clinical trials of BAV patients. Knockout animal models include tissue-specific and whole organism deletion of genes, and knock-in models are generated by introducing a specific human sequence variant into a similar gene in a model organism. BAV indicates bicuspid aortic valve; CNV, copy number variant; and GWA, genome-wide association.
It is therefore apparent that genetic alterations that lead to altered cellular signaling (ie, Notch, transforming growth factor-β) can cause BAV and associated aortic pathologies, such that establishing the genetic-to-pathology link is critical. The creation of banks of valve and aortic tissue from well-phenotyped patients operated on for aortic stenosis, aortic regurgitation, and aortic aneurysm will be critical for assessing the gene and protein expression patterns associated with the condition. The selection of appropriate controls for these studies is pivotal; they may include patients undergoing surgery for related conditions but without BAV, for example, those with aortic stenosis and tricuspid aortic valves. Developing animal models of BAV and its associated complications is a challenge, but it remains of crucial importance to deciphering the molecular pathology of BAV. Ultimately, further understanding of BAV at the molecular level may help identify novel markers of complications and targets for medical therapy.

Genetics

The aforementioned marked heterogeneity of BAV poses a major challenge to researchers whose aim is to identify genetic variants that cause BAV or predict BAV-associated complications. To address these challenges, specific goals need to be met. (1) A well-characterized BAV cohort that is followed over time should be established that is sufficiently large to permit association studies that are adequately powered to detect genetic variants with small or moderate effects leading to both BAV and its complications and to examine genetic determinants of rare outcomes or subtypes of BAV. Therefore, thousands of cases will be required to identify substantial genetic contributors. (2) To minimize bias due to misclassification, all cases in a BAV registry should be evaluated by experts in the field with the use of stringent, uniform criteria and standardized measurements. Adjudication of valve phenotypes and clinical end points by the appropriate imaging and outcomes cores will prevent misclassification and ensure the validity of findings. (3) Follow-up should be sufficiently long to capture the complications of BAV that may be slow to develop, such as aortic stenosis, with prioritized enrollment of patients who have not yet experienced complications. In most cases, this will require follow-up periods of >10 years; therefore, the inclusion of retrospectively identified patients will be critical, as long as accurate phenotype adjudication and standardized measurements are applied to current or previous available imaging. (4) A control cohort of imaging-negative, tricuspid aortic valve individuals should be recruited and followed in parallel with the BAV cohort. To minimize the confounding of associations due to systematic differences between cases and controls, it will be essential to compare BAV findings in appropriately matched tricuspid valve individuals who are equally well characterized and drawn from the same populations as the BAV cases. Associations can be distorted by ascertainment bias if convenience control groups, who may not have received the same level of diagnostic scrutiny, are acquired from registries or sample banks. (5) Families with inherited BAV should be prioritized for enrollment, because these families are more likely to have rare variants in single genes that can be identified by using whole exome or whole genome sequencing. Genes that were discovered to be altered in families with BAV, such as NOTCH1, are also found to be altered in sporadic cases and can provide a starting point for understanding the genetic architecture of BAV. Finally, as genetic risk factors for BAV and its complications are identified, the registry should be the foundation for clinical trials of gene-based tests or therapies for BAV patients who are at high risk for adverse outcomes to develop targeted medical therapies and to inform surgical decision making based on their individualized genetic risk profiles (Figure 8). Because many different genetic variants are likely to contribute to BAV outcomes, we envision a multicenter registry as a rich and continuous source of future genetic studies.

Disclosures

None.

References

18. Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T. Risk of late aortic events after an isolated aortic valve replacement for


Michelenla et al. Bicuspid Aortic Valve: Knowledge Gaps 2703


Downloaded from http://circ.ahajournals.org/ at WORLD HLTH ORGANIZATION on July 2, 2014


Key Words: aortic aneurysm, thoracic ■ aortic valve, bicuspid ■ aortic valve stenosis ■ heart defects, congenital